These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 21704809)
21. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Canto MI; Goggins M; Hruban RH; Petersen GM; Giardiello FM; Yeo C; Fishman EK; Brune K; Axilbund J; Griffin C; Ali S; Richman J; Jagannath S; Kantsevoy SV; Kalloo AN Clin Gastroenterol Hepatol; 2006 Jun; 4(6):766-81; quiz 665. PubMed ID: 16682259 [TBL] [Abstract][Full Text] [Related]
22. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754 [TBL] [Abstract][Full Text] [Related]
23. New strategies for the early detection of pancreatic cancer. Petrone MC; Arcidiacono PG Expert Rev Gastroenterol Hepatol; 2016; 10(2):157-9. PubMed ID: 26582179 [TBL] [Abstract][Full Text] [Related]
24. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Varadarajulu S; Tamhane A; Eloubeidi MA Gastrointest Endosc; 2005 Nov; 62(5):728-36; quiz 751, 753. PubMed ID: 16246688 [TBL] [Abstract][Full Text] [Related]
25. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Distler M; Pilarsky E; Kersting S; Grützmann R Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419 [TBL] [Abstract][Full Text] [Related]
26. A prediction rule for estimating pancreatic cancer risk in chronic pancreatitis patients with focal pancreatic mass lesions with prior negative EUS-FNA cytology. Cai QC; Chen Y; Xiao Y; Zhu W; Xu QF; Zhong L; Chen SY; Zhang MM; Wang LW; Li ZS Scand J Gastroenterol; 2011 Apr; 46(4):464-70. PubMed ID: 21114434 [TBL] [Abstract][Full Text] [Related]
27. Serum CA 242: the search for a valid marker of pancreatic cancer. Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807 [TBL] [Abstract][Full Text] [Related]
28. CEACAM1, a novel serum biomarker for pancreatic cancer. Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843 [TBL] [Abstract][Full Text] [Related]
29. Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Frossard JL; Amouyal P; Amouyal G; Palazzo L; Amaris J; Soldan M; Giostra E; Spahr L; Hadengue A; Fabre M Am J Gastroenterol; 2003 Jul; 98(7):1516-24. PubMed ID: 12873573 [TBL] [Abstract][Full Text] [Related]
30. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients. Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902 [TBL] [Abstract][Full Text] [Related]
31. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208 [TBL] [Abstract][Full Text] [Related]
32. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563 [TBL] [Abstract][Full Text] [Related]
33. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Chang JC; Kundranda M Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509 [TBL] [Abstract][Full Text] [Related]
34. Pretest prediction and diagnosis of metastatic lesions to the pancreas by endoscopic ultrasound-guided fine needle aspiration. Krishna SG; Bhattacharya A; Ross WA; Ladha H; Porter K; Bhutani MS; Lee JH J Gastroenterol Hepatol; 2015 Oct; 30(10):1552-60. PubMed ID: 25867963 [TBL] [Abstract][Full Text] [Related]
35. Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Canto MI Semin Oncol; 2007 Aug; 34(4):295-302. PubMed ID: 17674957 [TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707 [TBL] [Abstract][Full Text] [Related]
37. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. Choe JW; Kim JS; Kim HJ; Hwang SY; Joo MK; Lee BJ; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT Pancreas; 2016; 45(5):730-4. PubMed ID: 26646277 [TBL] [Abstract][Full Text] [Related]